Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.